La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Ascentage Pharma Group International Gestione

Gestione criteri di controllo 3/4

Ascentage Pharma Group International's Il CEO è Dajun Yang, nominato in Jan2009, e ha un mandato di 15.58 anni. la retribuzione annua totale è CN¥ 4.78M, composta da 94.7% di stipendio e 5.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.025% delle azioni della società, per un valore di € 248.76K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.8 anni e 5.2 anni.

Informazioni chiave

Dajun Yang

Amministratore delegato

CN¥4.8m

Compenso totale

Percentuale dello stipendio del CEO	94.7%
Mandato del CEO	15.7yrs
Proprietà del CEO	0.02%
Durata media del management	5.9yrs
Durata media del Consiglio di amministrazione	5.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Dajun Yang rispetto agli utili di Ascentage Pharma Group International?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-CN¥360m
Mar 31 2024	n/a	n/a	-CN¥643m
Dec 31 2023	CN¥5m	CN¥5m	-CN¥926m
Sep 30 2023	n/a	n/a	-CN¥902m
Jun 30 2023	n/a	n/a	-CN¥879m
Mar 31 2023	n/a	n/a	-CN¥881m
Dec 31 2022	CN¥4m	CN¥4m	-CN¥883m
Sep 30 2022	n/a	n/a	-CN¥848m
Jun 30 2022	n/a	n/a	-CN¥812m
Mar 31 2022	n/a	n/a	-CN¥797m
Dec 31 2021	CN¥5m	CN¥5m	-CN¥782m
Sep 30 2021	n/a	n/a	-CN¥759m
Jun 30 2021	n/a	n/a	-CN¥735m
Mar 31 2021	n/a	n/a	-CN¥706m
Dec 31 2020	CN¥4m	CN¥4m	-CN¥678m
Sep 30 2020	n/a	n/a	-CN¥922m
Jun 30 2020	n/a	n/a	-CN¥1b
Mar 31 2020	n/a	n/a	-CN¥1b
Dec 31 2019	CN¥4m	CN¥3m	-CN¥1b

Compensazione vs Mercato: La retribuzione totale di Dajun ($USD 669.67K ) è inferiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.43M ).

Compensazione vs guadagni: La retribuzione di Dajun è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Dajun Yang (61 yo)

15.7yrs

Mandato

CN¥4,781,000

Compensazione

Dr. Dajun Yang, M.D., Ph D Co-Founded Ascentage Pharma Group International in 2019 and serves as its Chairman and has been its Director since November 17, 2017 and serves as its CEO since July 2018. His...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Dajun Yang	Co-Founder	15.7yrs	CN¥4.78m	0.025% CN¥ 356.6k
Shaomeng Wang	Co-Founder	no data	CN¥1.17m	Nessun dato
Ming Guo	Co-Founder	15.3yrs	Nessun dato	Nessun dato
Thomas Knapp	Senior VP & General Counsel	5.5yrs	Nessun dato	Nessun dato
Yifan Zhai	Chief Medical Officer	no data	Nessun dato	0.041% CN¥ 583.6k
Douglas Fang	Senior Vice President of Preclinical Development	no data	Nessun dato	Nessun dato
Jianfeng Wen	Senior Vice President of Pharmaceutical Science	no data	Nessun dato	Nessun dato
Raymond Kmetz	Chief Business Officer	5.6yrs	Nessun dato	Nessun dato
Yifei Zhu	Chief Commercial Officer	1.4yrs	Nessun dato	Nessun dato
Cheung Ki Wong	Company Secretary	6.2yrs	Nessun dato	Nessun dato

5.9yrs

Durata media

61yo

Età media

Gestione esperta: Il team dirigenziale di 36X è esperto e expertise (durata media dell'incarico 5.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Dajun Yang	Co-Founder	6.8yrs	CN¥4.78m	0.025% CN¥ 356.6k
Shaomeng Wang	Co-Founder	6.8yrs	CN¥1.17m	Nessun dato
Allen S. Lichter	Chairman of the Clinical Advisory Board	1.7yrs	Nessun dato	Nessun dato
Paul A. Bunn	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
David Sidransky	Independent Non-Executive Director	3.5yrs	CN¥510.00k	Nessun dato
Jedd D. Wolchok	Member of Clinical Advisory Board	3.4yrs	Nessun dato	Nessun dato
Arul M. Chinnaiyan	Member of Clinical Advisory Board	no data	Nessun dato	Nessun dato
Changqing Ye	Independent Non-Executive Director	5.3yrs	CN¥502.00k	Nessun dato
Dazhong Lu	Non-Executive Director	6.2yrs	CN¥25.00k	Nessun dato
Wei Ren	Independent Non-Executive Director	5.3yrs	CN¥502.00k	Nessun dato
Asher A. Chanan-Khan	Member of Clinical Advisory Board	1.7yrs	Nessun dato	Nessun dato

5.3yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 36X sono considerati esperti (durata media dell'incarico 5.2 anni).

Ascentage Pharma Group International Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Ascentage Pharma Group International Announces Board and Committee Changes

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

High number of new directors

High number of new directors

Ascentage Pharma Group International Announces Management Changes, Effective May 20, 2022

Less than half of directors are independent

Recent updates

Forecast to breakeven in 2026

First half 2024 earnings released: EPS: CN¥0.56 (vs CN¥1.47 loss in 1H 2023)

New major risk - Revenue and earnings growth

Ascentage Pharma Clears to Initiate A Registrational Phase III Study of Lisaftoclax, by the Center for Drug Evaluation of China National Medical Products Administration

Ascentage Pharma Group International to Report First Half, 2024 Results on Aug 22, 2024

New minor risk - Shareholder dilution

Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib (HQP1351)

Ascentage Pharma Group International Announces Board and Committee Changes

New major risk - Share price stability

Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%

Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting

Ascentage Pharma Group International, Annual General Meeting, May 10, 2024

Full year 2023 earnings released: CN¥3.28 loss per share (vs CN¥3.35 loss in FY 2022)

Ascentage Pharma Group International to Report Fiscal Year 2023 Results on Mar 27, 2024

Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib (HQP1351) in Patients with Chronic-Phase Chronic Myeloid Leukemia

Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia (CML) Management from the National Comprehensive Cancer Network (NCCN)

Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib

Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR

Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication

China National Medical Products Administration Approves Olverembatinib for Treatment of Cml-Cp Patients

Ascentage Pharma Group International to Present Results from Multiple Clinical Studies of olverembatinib and APG-2575 at the 2023 American Society of Hematology(ASH) Annual Meeting, two of which have been Selected for Oral Reports

Ascentage Pharma Releases Latest Data of Pelcitoclax (Apg-1252) Combined with Osimertinib Demonstrates Potential as A New Treatment Option for Tp53-And Egfr-Mutant Nsclc

Ascentage Pharma Announces First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia

Ascentage Pharma Announces Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment Naïve Patients with CLL/SLL Approved by the China CDE

First half 2023 earnings released: CN¥1.47 loss per share (vs CN¥1.54 loss in 1H 2022)

Ascentage Pharma Announces Clearance for Global Registrational Phase III Trial

Ascentage Pharma Group International to Report First Half, 2023 Results on Aug 21, 2023

Ascentage Pharma Group International Receives Clearance from the U.S. Food and Drug Administration to Initiate A Phase 3 Registrational Trial of Lisaftoclax

New minor risk - Share price stability

Ascentage Pharma Group International Announces CDE's Approval for the Phase III Pivotal Study in China of Olverembatinib for the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ All)

Ascentage Pharma Group International Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Ascentage Pharma Group International Recommends Breakthrough Therapy Designation in China for the Treatment of Sdh-Deficient GIST

Ascentage Pharma Group International Presents Results from Four Studies at 2023 American Society of Clinical Oncology Annual Meeting

Full year 2022 earnings released: CN¥3.35 loss per share (vs CN¥3.07 loss in FY 2021)

Ascentage Pharma Group International has completed a Follow-on Equity Offering in the amount of HKD 550.125 million.

Ascentage Pharma Group International's Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

Ascentage Pharma Group International Releases Preliminary Results from a Global Phase II Study of Lisaftoclax

Ascentage Pharma Delivers Oral Report on the First Dataset from the US Study of Olverembatinib (HQP1351) with Promising Efficacy Observed in Patients Who Failed Prior Treatment with Ponatinib

Ascentage Pharma's Global Industrial Base Obtains Drug Production Enterprise License

Ascentage Pharma Group International Announces IND Approval in China for Phase I Study of APG-5918 in Patients with Advanced Solid Tumors or Hematologic Malignancies

Ascentage Pharma Group International Announces Released Results from A Phase I Study of the Investigational Inhibitor of Apoptosis Protein (Iap) Antagonist Apg-1387 in Chinese Patients with Chronic Hepatitis B

Ascentage Pharma Releases Phase I Results of Iap Antagonist Apg-1387 in an Oral Report Showing Potential for Functionally Curing Chb

Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, At the ASH Annual Meeting

Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Ascentage Pharma Announces Phase I/Ii Data of Olverembatinib (Hqp1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-In-Class Potential

First half 2022 earnings released: CN¥1.54 loss per share (vs CN¥1.53 loss in 1H 2021)

Ascentage Pharma Group International to Report Q2, 2022 Results on Aug 26, 2022

High number of new directors

Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada

Ascentage Pharma Announces China National Medical Products Administration Accepts and Grants Priority Review Designation to Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML

Ascentage Pharma Group International Announces Ind Clearance by the Us Fda for First-In-Human Study of Novel Eed Inhibitor Apg-5918

Ascentage Pharma Group International Releases Results from A Phase I Study of the Company's Novel Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R Nhl) at the 2022 European Hematology Association Hybrid Congress

Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL

Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC

Ascentage Pharma Group International Releases the Updated Results from A Phase II Study of the Mdm2-P53 Inhibitor Alrizomadlin (APG-115) Plus Pembrolizumab in Adults and Children with Various Solid Tumors in A Poster Discussion Session At the ASCO Annual Meeting

Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development

High number of new directors

Ascentage Pharma Group to Present Latest Clinical Data of Bcl-2 Inhibitorlisaftoclax (Apg-2575) in Patients with Relapsed/Refractory Non-Hodgkinlymphomas At 2022 European Hematology Association Hybrid Congress

Ascentage Pharma Group International Announces Management Changes, Effective May 20, 2022

Ascentage Pharma Group International Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in Embo Molecular Medicine

Less than half of directors are independent

Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

Ascentage Pharma Group International, Annual General Meeting, May 19, 2022

Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including A China Study Demonstrating Complete Responses

Ascentage Pharma Announces CDE's Approval for the Phase II Pivotal Study in China of the Bcl-2 Inhibitor Lisaftoclax (APG-2575) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Clover Biopharmaceuticals, Ltd. and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human Trail-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis

Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib

Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Grants Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma